Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II)in patients with advanced adenocarcinoma of the lung

R. T. Eagan; S. Frytak; J. N. Ingle; E. T. Creagan; W. C. Nichols; L. K. Kvols

Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II)in patients with advanced adenocarcinoma of the lung

R. T. Eagan, S. Frytak, J. N. Ingle, E. T. Creagan, W. C. Nichols, L. K. Kvols

Medical Oncology

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

In an attempt to improve upon the 43%-48% regression rates noted for various CAP regimens consisting of cyclophosphamide,doxorubicin (Adriamycin), and cis-diamminedichloroplatinum(II) in various doses and schedules, triazinate was added to tht three-drug combination, and the new combination (T-CAP) was evaluated inpatients with advanced adenocarcinoma of the lung.(T-CAP) produced a regression rate of 57% with a 7-week increase in overall median time to progression and a 4-weeks incrase in overall median survival compared to the best of the CAP schedules. More stomatitis and dermatitis were noted with he new combination, but myelosuppression was similar to that of the CAP regimens. These data suggest that further studies wih triazinate should be conducted in patients with adenocarcinoma of the lung.

Original language	English (US)
Pages (from-to)	925-928
Number of pages	4
Journal	Cancer Treatment Reports
Volume	64
Issue number	8-9
State	Published - Dec 1 1980

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{ef643a5c7a5240bdb2e435f1277f8f39,

title = "Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II)in patients with advanced adenocarcinoma of the lung",

abstract = "In an attempt to improve upon the 43%-48% regression rates noted for various CAP regimens consisting of cyclophosphamide,doxorubicin (Adriamycin), and cis-diamminedichloroplatinum(II) in various doses and schedules, triazinate was added to tht three-drug combination, and the new combination (T-CAP) was evaluated inpatients with advanced adenocarcinoma of the lung.(T-CAP) produced a regression rate of 57% with a 7-week increase in overall median time to progression and a 4-weeks incrase in overall median survival compared to the best of the CAP schedules. More stomatitis and dermatitis were noted with he new combination, but myelosuppression was similar to that of the CAP regimens. These data suggest that further studies wih triazinate should be conducted in patients with adenocarcinoma of the lung.",

author = "Eagan, {R. T.} and S. Frytak and Ingle, {J. N.} and Creagan, {E. T.} and Nichols, {W. C.} and Kvols, {L. K.}",

year = "1980",

month = dec,

day = "1",

language = "English (US)",

volume = "64",

pages = "925--928",

journal = "Cancer Treatment Reports",

issn = "0361-5960",

publisher = "Oxford University Press",

number = "8-9",

}

TY - JOUR

T1 - Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II)in patients with advanced adenocarcinoma of the lung

AU - Eagan, R. T.

AU - Frytak, S.

AU - Ingle, J. N.

AU - Creagan, E. T.

AU - Nichols, W. C.

AU - Kvols, L. K.

PY - 1980/12/1

Y1 - 1980/12/1

N2 - In an attempt to improve upon the 43%-48% regression rates noted for various CAP regimens consisting of cyclophosphamide,doxorubicin (Adriamycin), and cis-diamminedichloroplatinum(II) in various doses and schedules, triazinate was added to tht three-drug combination, and the new combination (T-CAP) was evaluated inpatients with advanced adenocarcinoma of the lung.(T-CAP) produced a regression rate of 57% with a 7-week increase in overall median time to progression and a 4-weeks incrase in overall median survival compared to the best of the CAP schedules. More stomatitis and dermatitis were noted with he new combination, but myelosuppression was similar to that of the CAP regimens. These data suggest that further studies wih triazinate should be conducted in patients with adenocarcinoma of the lung.

AB - In an attempt to improve upon the 43%-48% regression rates noted for various CAP regimens consisting of cyclophosphamide,doxorubicin (Adriamycin), and cis-diamminedichloroplatinum(II) in various doses and schedules, triazinate was added to tht three-drug combination, and the new combination (T-CAP) was evaluated inpatients with advanced adenocarcinoma of the lung.(T-CAP) produced a regression rate of 57% with a 7-week increase in overall median time to progression and a 4-weeks incrase in overall median survival compared to the best of the CAP schedules. More stomatitis and dermatitis were noted with he new combination, but myelosuppression was similar to that of the CAP regimens. These data suggest that further studies wih triazinate should be conducted in patients with adenocarcinoma of the lung.

UR - http://www.scopus.com/inward/record.url?scp=0019253214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019253214&partnerID=8YFLogxK

M3 - Article

C2 - 7192602

AN - SCOPUS:0019253214

SN - 0361-5960

VL - 64

SP - 925

EP - 928

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

IS - 8-9

ER -

Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II)in patients with advanced adenocarcinoma of the lung

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this